Renejix – Small Molecule CDMO (USA)
It is typical to encounter a restricted number of APIs during the initial stages of drug development. This limitation hinders the swift advancement of the development process. Renejix introduces an innovative strategy that facilitates the utilization of large-scale machinery right from the outset, potentially leading to the production of cGMP batches with favorable yields.
This document provides both a high-level overview of Renejix’s stand-alone small molecule analytical services, and a detailed list of services organized by…
Quality by Design (QbD) is a well-known pharmaceutical industry strategy for enhancing production processes, including active pharmaceutical ingredients and medicinal products. Companies…
Please check out the below links to access our list of equipments available at the respective locations1. Hauppauge, New York2. Islip, New…
If scientific literature indicates that elements are not likely to be present in drug product components, and no additional elements are added…
A newly formed pharmaceutical company was creating a novel cardiometabolic drug, a new small molecule, that was in Phase 2a testing in…
Direct-to-Patient Clinical Supply Services: Amid the surge in remote clinical studies, the imperative of facilitating direct-to-patient distribution of clinical supplies has gained…